CZ304602B6 - Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu) - Google Patents

Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu) Download PDF

Info

Publication number
CZ304602B6
CZ304602B6 CZ2009-584A CZ2009584A CZ304602B6 CZ 304602 B6 CZ304602 B6 CZ 304602B6 CZ 2009584 A CZ2009584 A CZ 2009584A CZ 304602 B6 CZ304602 B6 CZ 304602B6
Authority
CZ
Czechia
Prior art keywords
duloxetine hydrochloride
solvent
crystalline duloxetine
crystalline
crystals
Prior art date
Application number
CZ2009-584A
Other languages
Czech (cs)
English (en)
Other versions
CZ2009584A3 (cs
Inventor
Luděk Ridvan
Josef Cinibulk
Veronika Grünwaldová
Hana Brusová
Original Assignee
Zentiva, K. S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, K. S. filed Critical Zentiva, K. S.
Priority to CZ2009-584A priority Critical patent/CZ304602B6/cs
Priority to BR112012004862A priority patent/BR112012004862A2/pt
Priority to EA201290127A priority patent/EA021528B1/ru
Priority to PCT/CZ2010/000099 priority patent/WO2011026449A1/en
Priority to KR1020127004225A priority patent/KR20120047262A/ko
Priority to CN2010800392370A priority patent/CN102482254A/zh
Priority to MX2012002621A priority patent/MX2012002621A/es
Priority to EP10771629A priority patent/EP2473497A1/en
Priority to JP2012527196A priority patent/JP2013503823A/ja
Publication of CZ2009584A3 publication Critical patent/CZ2009584A3/cs
Priority to IL218329A priority patent/IL218329A0/en
Priority to ZA2012/01570A priority patent/ZA201201570B/en
Publication of CZ304602B6 publication Critical patent/CZ304602B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CZ2009-584A 2009-09-02 2009-09-02 Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu) CZ304602B6 (cs)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CZ2009-584A CZ304602B6 (cs) 2009-09-02 2009-09-02 Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
CN2010800392370A CN102482254A (zh) 2009-09-02 2010-09-02 (s)-n-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺盐酸盐(度洛西汀)的结晶方法
EA201290127A EA021528B1 (ru) 2009-09-02 2010-09-02 Способ кристаллизации (s)-n-метил-3-(1-нафтилокси)-3-(2-тиенил)пропиламина гидрохлорида (дулоксетина)
PCT/CZ2010/000099 WO2011026449A1 (en) 2009-09-02 2010-09-02 A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine)
KR1020127004225A KR20120047262A (ko) 2009-09-02 2010-09-02 (ｓ)-ｎ-메틸-3-(1-나프틸옥시)-3-(2-티에닐)프로필아민 하이드로클로라이드(듀록세틴)의 결정화 방법
BR112012004862A BR112012004862A2 (pt) 2009-09-02 2010-09-02 método para a preparação de um composto , duloxetina cristalina, e, composição farmacêutica
MX2012002621A MX2012002621A (es) 2009-09-02 2010-09-02 Un metodo de cristalizacion de clorhidrato de (s)-n-metil-3-(1-naftiloxi)-3-(2-tienil)propilamina (duloxetina).
EP10771629A EP2473497A1 (en) 2009-09-02 2010-09-02 A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine)
JP2012527196A JP2013503823A (ja) 2009-09-02 2010-09-02 （ｓ）‐ｎ‐メチル‐３‐（１‐ナフチルオキシ）‐３‐（２‐チエニル）プロピルアミン塩酸塩（デュロキセチン）の結晶化方法
IL218329A IL218329A0 (en) 2009-09-02 2012-02-27 A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine)
ZA2012/01570A ZA201201570B (en) 2009-09-02 2012-03-01 A method of crystallization of (s)-n-methyl-3-1(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CZ2009-584A CZ304602B6 (cs) 2009-09-02 2009-09-02 Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)

Publications (2)

Publication Number Publication Date
CZ2009584A3 CZ2009584A3 (cs) 2011-03-09
CZ304602B6 true CZ304602B6 (cs) 2014-07-30

Family

ID=43413356

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2009-584A CZ304602B6 (cs) 2009-09-02 2009-09-02 Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)

Country Status (11)

Country Link
EP (1) EP2473497A1 (ja)
JP (1) JP2013503823A (ja)
KR (1) KR20120047262A (ja)
CN (1) CN102482254A (ja)
BR (1) BR112012004862A2 (ja)
CZ (1) CZ304602B6 (ja)
EA (1) EA021528B1 (ja)
IL (1) IL218329A0 (ja)
MX (1) MX2012002621A (ja)
WO (1) WO2011026449A1 (ja)
ZA (1) ZA201201570B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
CN104478849A (zh) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 制备去甲肾上腺素再摄取双重抑制剂的方法
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法
JP2016222628A (ja) * 2015-06-03 2016-12-28 株式会社トクヤマ デュロキセチン塩酸塩の製造方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276660A1 (en) * 2005-03-14 2006-12-07 Santiago Ini Process for the purification of duloxetine hydrochloride
WO2007093439A1 (en) * 2006-02-17 2007-08-23 Krka Processes for the preparation of crystalline forms of duloxetine hydrochloride
WO2007148096A1 (en) * 2006-06-23 2007-12-27 Arrow International Limited Crystalline duloxetine hydrochloride
WO2008107911A2 (en) * 2007-03-05 2008-09-12 Lupin Limited Novel process for preparation of duloxetine hydrochloride
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
DE10212301A1 (de) 2002-03-20 2003-10-02 Bayer Ag Verfahren zur Herstellung von Aryl-aminopropanolen
CA2491472C (en) 2002-07-09 2011-09-27 Lonza Ag Process for the preparation of n-monosubstituted .beta.-amino alcohols
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
CZ297560B6 (cs) * 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
GB0612509D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276660A1 (en) * 2005-03-14 2006-12-07 Santiago Ini Process for the purification of duloxetine hydrochloride
WO2007093439A1 (en) * 2006-02-17 2007-08-23 Krka Processes for the preparation of crystalline forms of duloxetine hydrochloride
WO2007148096A1 (en) * 2006-06-23 2007-12-27 Arrow International Limited Crystalline duloxetine hydrochloride
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
WO2008107911A2 (en) * 2007-03-05 2008-09-12 Lupin Limited Novel process for preparation of duloxetine hydrochloride

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bhadbhade M., Hook J., et al.: Acta Crystallographica Section E (2009), E65, o 2294, supplementary materials *

Also Published As

Publication number Publication date
MX2012002621A (es) 2012-07-03
BR112012004862A2 (pt) 2015-09-08
IL218329A0 (en) 2012-04-30
KR20120047262A (ko) 2012-05-11
CN102482254A (zh) 2012-05-30
EA201290127A1 (ru) 2013-02-28
WO2011026449A1 (en) 2011-03-10
JP2013503823A (ja) 2013-02-04
EP2473497A1 (en) 2012-07-11
ZA201201570B (en) 2013-08-28
EA021528B1 (ru) 2015-07-30
CZ2009584A3 (cs) 2011-03-09

Similar Documents

Publication Publication Date Title
JP6239977B2 (ja) 肥満治療用の医薬組成物
JP2644234B2 (ja) 形態学的に均質型のチアゾール誘導体の製造方法
BRPI0617477A2 (pt) mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
CA2988393C (en) Solid state forms of sofosbuvir
CZ304602B6 (cs) Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
JP7264999B2 (ja) ２－（１－アシルオキシ－ｎ－ペンチル）安息香酸と塩基性アミノ酸またはアミノグアニジンによって形成される塩と、その製造方法及び用途
US20080234323A1 (en) Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
EP2271612A2 (en) Rasagiline mesylate particles and process for the preparation thereof
JP5552575B2 (ja) アルツハイマー病治療用医薬の製造におけるα−マンゴスチンの使用
RU2485121C1 (ru) Новые кристаллические формы адефовира дипивоксила и способы его получения
WO2024060373A1 (zh) 一种s-(+)-氟比洛芬盐及其制备方法、药物组合物和用途
JPWO2005103017A1 (ja) 難溶性薬物の比表面積増大方法
CN115043820B (zh) Par-1抑制剂及其类似物的制备方法和在血栓性疾病防治中的应用
JP2014521710A (ja) 新規ソフトｐｄｅ４阻害剤
US20090202647A1 (en) Solid form of racemic rotigotine
CN108699094A (zh) 一种钠依赖性葡萄糖共转运蛋白抑制剂的胺溶剂合物及其制备方法和应用
AU2007274477B2 (en) Novel crystal of substituted phenylalkanoic acid and production process
CN114702477B (zh) 哌嗪桥连的硝基咪唑萘酰亚胺类化合物及其制备方法和应用
WO2011085130A1 (en) Solid state forms of fosamprenavir calcium salt and process for preparation thereof
JP5904997B2 (ja) 神経細胞のアポトーシス又は神経変性を阻害するための医薬組成物
RU2778508C1 (ru) Кристаллическая форма моноэтаноламин 3'-[(2Z)-2-[1-(3,4-диметилфенил)-1,5-дигидро-3-метил-5-оксо-4Н-пиразол-4-илиден]гидразино]-2'-гидрокси-[1,1'-бифенил]-3-карбоновой кислоты
EP1646607B1 (en) A method for the preparation of crystalline dexloxiglumide
JP2018524340A (ja) チアジドアミド誘導体とその利用
TWI532709B (zh) An amine salt of an amine benzoic acid derivative and a process for producing the same
CA3060481A1 (en) Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20190902